famotidine has been researched along with Adenocarcinoma Of Kidney in 3 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Famotidine may increase IL-2 internalization by the IL-2 receptor on T-lymphocytes." | 5.35 | Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. ( King, LA; Quan, FM; Quan, WD; Walker, PR, 2008) |
| "High-dose, continuous-infusion interleukin-2 (IL-2) followed by pulse dose and concurrent administration of famotidine has demonstrated response rates of 64% and 33% in patients with metastatic melanoma and metastatic renal cell carcinoma, respectively." | 4.84 | Nursing care of patients receiving high-dose, continuous-infusion interleukin-2 with pulse dose and famotidine. ( Quan, W; Tyre, CC, 2007) |
| "Famotidine may enhance the LAK activity by increasing IL-2 internalization by the IL-2 receptor on lymphocytes." | 1.40 | Activity of outpatient intravenous interleukin-2 and famotidine in metastatic clear cell kidney cancer. ( Quan, FM; Quan, WD, 2014) |
| "Famotidine may increase IL-2 internalization by the IL-2 receptor on T-lymphocytes." | 1.35 | Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. ( King, LA; Quan, FM; Quan, WD; Walker, PR, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Quan, WD | 2 |
| Quan, FM | 2 |
| Tyre, CC | 1 |
| Quan, W | 1 |
| King, LA | 1 |
| Walker, PR | 1 |
1 review available for famotidine and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
Nursing care of patients receiving high-dose, continuous-infusion interleukin-2 with pulse dose and famotidine.
Topics: Anti-Ulcer Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Drug | 2007 |
2 other studies available for famotidine and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
Activity of outpatient intravenous interleukin-2 and famotidine in metastatic clear cell kidney cancer.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2014 |
Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Cycloph | 2008 |